Cancer
Care - St. Luke's Mountain States Tumor Institute
Research and Clinical Trials
| Clinical Trials |
Find clinical trials based on cancer types, stage, previous treatment, daily activity, and zip code. |
Research efforts at St. Luke's Mountain States Tumor Institute (MSTI) are important in the development of new drugs and procedures that can improve cancer treatment results and reduce side effects, and in the development of methods and techniques that aid in the early detection and prevention of cancer.
Because of its nationally respected expertise, St. Luke's MSTI is asked to participate in numerous clinical research protocols in cooperation with regional and national cancer research groups and pharmaceutical firms.
Among these research groups are the National Cancer Institute, Fred Hutchison Cancer Center, Mountain States Tumor and Medical Research Institute (MSTMRI), Children's Oncology Group, Puget Sound Oncology Consortium, and the Southwest Oncology Group, all of which share important information about the latest developments in cancer treatments that benefit patients.
Learn more about research at St. Luke's
PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial
St. Luke's MSTI
was selected to participate as a satellite of the University
of Utah in the PLCO (Prostate, Lung, Colorectal, and Ovarian)
Cancer Screening Trial, a long-term study sponsored by
the National Cancer Institute (NCI).
This study is designed
to determine if screening tests intended to detect these
cancers at an early stage will be able to reduce deaths
from these malignancies. The trial will also help researchers
learn more about the causes of these cancers and how to
prevent them in the future.
National Lung Screening Trial (NLST)
St. Luke’s MSTI is a participant in the National Lung Screening Trial (NLST), sponsored by the National Cancer Institute. The study was initiated in October 2002 and closed to enrollment in February 2004, with 1,620 participants.
The purpose of the study is to compare Spiral CT exams and chest X-rays as screening tools in the early detection of lung cancer in high-risk individuals. Participants (long-term smokers) were randomized into one of two arms – spiral CT or chest X-ray. Each participant received three exams over two years.
The NLST is now starting its seventh year, and will continue until 2009 with participant long-term follow-up. During this period, participants will be contacted in regard to their health status, and may have follow-up examinations.
Detection of lung cancer at an early stage increases the chance of a cure.
For more information on the NLST, visit http://www.nci.nih.gov/NLST or call 1-800-716-0499.
SELECT
(Selenium and Vitamin E Cancer Prevention Trial)
St. Luke's MSTI
was selected to participate in the largest cancer prevention
trial ever undertaken. This clinical research trial, known
as SELECT, evaluates the affect of selenium and vitamin
E in the prevention of prostate cancer. The overall goal
is to enroll 32,000 male patients in a five-year period
and to follow each patient for many years to determine
the impact of treatment on the likelihood of development
of prostate cancer.
Interested in clinical trials?
St. Luke's MSTI is pleased to offer TrialCheck ®.
TrialCheck is a free comprehensive searchable database of cancer clinical trials
that offers the very latest in treatment information.
With TrialCheck, patients and caregivers can easily locate clinical trials based on patient-specific criteria such as cancer types, stage, previous treatment, daily activity, and zip code.
